Arrhythmias & electrophysiology
Incidence and Clinical Management of Supraventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Authors' conclusion
In comparison with prior studies, the incidence of SVAs in this large, single-center CPVT cohort was substantially lower (8.3% vs 26%-35%). Although a larger multicenter study is needed to confirm, this study suggests that radiofrequency ablation durably treats CPVT-associated SVAs.
Study context
- Population
- Patients diagnosed clinically with catecholaminergic polymorphic ventricular tachycardia (CPVT) between January 2000 and September 202351% female, average age at diagnosis 21 ± 17 years
- Participants
- 206 patients
- Outcome
- Incidence of SVA
Methodological detailselectronic medical records reviewed
- Electronic medical records reviewed
Main finding
As reported in the abstract
Patients with evidence of an SVA
17 (8.3%) of 206
Atrial fibrillation (AF)/atrial flutter (AFL)
8
Atrial tachycardia (AT)
9
Supraventricular tachycardia
1
Observational data: associations, not effects.
Further findings
Age at SVA diagnosis
- Median age at SVA diagnosis
- 28 years (Q1-Q3: 16-34 years)
Symptoms
- Symptomatic
- 11 (65%) of 17
- Of the symptomatic patients, experienced inappropriate shocks
- 3 (27%)
Management
- Underwent radiofrequency ablation
- 5 (29%) of 17
- All patients were trialed on antiarrhythmics
- Owing to drug failure, intolerance, or patient/provider preference
SVA recurrence · median follow-up 11 months (Q1-Q3: 5-45 months)
- SVA recurrence in a patient treated medically
- 1
Original publication
Incidence and Clinical Management of Supraventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol. Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →